United Healthcare Community Plan

Pharmacy PA Call Center: 1-800-310-6826
Fax this form to 1-866-940-7328

HEPATITIS C AGENTS PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Hepatitis C Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at: https://www.pa.gov/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.

Office contact name/phone:		Prescriber name:		
LTC facility contact/phone:		State license #:	NPI:	
Total # pages:		Street address:		
Beneficiary name:		City/state/zip:		
Beneficiary ID#:	DOB:	Phone:	Fax:	
Requested drug #1:	Directions:	Qty:	☐ 8 weeks ☐ 16 weeks ☐ 12 weeks ☐ Other: _____	
Requested drug #2:	Directions:	Qty:	☐ 8 weeks ☐ 16 weeks ☐ 12 weeks ☐ Other: _____	
Is the beneficiary currently being treated with the requested drug(s)?	☐ Yes – Therapy start date: _____	☐ No		

SUBMIT DOCUMENTATION from the medical record for all items below.

For requests for NON-PREFERRED Hepatitis C Agents direct-acting antivirals (DAAs):

1. Documentation that the beneficiary tried and failed or has a contraindication or intolerance to the preferred Hepatitis C Agents. *(See the Preferred Drug List for the list of preferred Hepatitis C Agents at: https://papdl.com/preferred-drug-list.)*
2. Cirrhosis assessment documented by a recent noninvasive test and date of testing.
3. Genotype if one of the following (check the appropriate box for the beneficiary):
   - ☐ The beneficiary is prescribed a non-pangenotypic regimen.
   - ☐ The beneficiary is hepatitis C sofosbuvir-based, sofosbuvir-velpatasvir-voxilaprevir, or sofosbuvir plus glecaprevir-pibrentasvir treatment-experienced.
   - ☐ The beneficiary has decompensated cirrhosis and is prescribed ledipasvir-sofosbuvir.
   - ☐ The beneficiary is treatment-naïve (with cirrhosis) and prescribed sofosbuvir-velpatasvir.
4. RAS (resistance-associated substitutions) testing and date of testing if one of the following (check the appropriate box for the beneficiary):
   - ☐ The beneficiary is genotype 1a and prescribed elbasvir-grazoprevir.
   - ☐ The beneficiary is genotype 1a, treatment-experienced, and prescribed ledipasvir-sofosbuvir.
   - ☐ The beneficiary is genotype 3, treatment-naïve (with cirrhosis) or treatment-experienced (without cirrhosis) and prescribed 12 weeks of sofosbuvir-velpatasvir.

For requests for THERAPEUTIC DUPLICATION of Hepatitis C Agents direct-acting antivirals (DAAs):

For a beneficiary taking more than 1 Hepatitis C Agents DAA product concomitantly:

- ☐ The beneficiary has a medical reason for concomitant use of the requested products that is supported by peer-reviewed medical literature or national treatment guidelines.

For requests for ALL OTHER NON-PREFERRED Hepatitis C Agents (e.g., Pegasys): Diagnosis: _____

☐ The beneficiary has a history of therapeutic failure of or a contraindication or an intolerance to first line therapies.

ATTESTATION from the prescriber for one of the items below.

Check the appropriate box for the beneficiary.

☐ The beneficiary is hepatitis C treatment naïve.
☐ The beneficiary has been treated for hepatitis C with the following treatment regimen: _____

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	**Date**:

Pharmacy PA Call Center: 1-800-310-6826
Fax this form to 1-866-940-7328